D. E. Shaw & Co., Inc. Next Cure, Inc. Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.2 - $3.07 $16,632 - $42,550	13,860 New	13,860 $19,000
Q4 2021 Feb 14, 2022	SELL	$5.7 - $9.1 $72,823 - $116,261	-12,776 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$6.74 - $8.02 $163,269 - $194,276	-24,224 Reduced 65.47%	12,776 $86,000
Q2 2021 Aug 16, 2021	SELL	$7.6 - $10.28 $55,875 - $75,578	-7,352 Reduced 16.58%	37,000 $297,000
Q1 2021 May 17, 2021	BUY	$9.81 - $13.88 $29,420 - $41,626	2,999 Added 7.25%	44,352 $444,000
Q4 2020 Feb 16, 2021	BUY	$9.47 - $12.43 $391,612 - $514,017	41,353 New	41,353 $451,000
Q3 2020 Nov 16, 2020	SELL	$8.15 - $21.17 $637,101 - $1.65 Million	-78,172 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$21.19 - $40.2 $1.66 Million - $3.14 Million	78,172 New	78,172 $1.68 Million
Q1 2020 May 15, 2020	SELL	$32.32 - $58.37 $784,309 - $1.42 Million	-24,267 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$25.0 - $92.22 $606,675 - $2.24 Million	24,267 New	24,267 $1.37 Million

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $26.9M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.